(5α,17β)-N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4- Aza -androst-1-ene-17-carboxamide (5α,17β)-N-[2,5-双(三氟甲基)苯基]-3-氧代-4-氮杂-雄烷-1-烯-17-甲酰胺
CAS 164656-23-9 MFCD00937869
化学结构图
SMILES: C[C@@]12CC[C@@H]3[C@H](CC[C@@H]4NC(=O)C=C[C@]43C)[C@H]1CC[C@H]2C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F |&1:1,4,5,8,14,16,19|
化学属性
| Mol. Formula | C27H30F6N2O2 |
|---|---|
| Mol. Weight | 528.53 |
别名和识别编码
| Chemical Name | (5α,17β)-N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4- Aza -androst-1-ene-17-carboxamide |
|---|---|
| CAS Number | 164656-23-9 |
| Alfabeta Name | DUTASTERIDE |
| MDL Number | MFCD00937869 |
| Chemical Name Translation | (5α,17β)-N-[2,5-双(三氟甲基)苯基]-3-氧代-4-氮杂-雄烷-1-烯-17-甲酰胺 |
| LabNetwork Molecule ID | LN00177509 |
| Formula | C27H30F6N2O2 |
| Synonym | LS-173584; LS 173584; LS173584; Dutasteride; Brand name: Avodart; Avidart; Avolve; Duagen; Dutas; Dutagen; Duprost. |
| IUPAC Name | (4aR,6aS,7S,9aS,9bS,11aR)-N-(2,5-bis(trifluoromethyl)phenyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide |
| InChIKey | JWJOTENAMICLJG-VYZSUTEISA-N |
| InChI | InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17?,19+,21+,24-,25+/m0/s1 |
| Canonical SMILES | C[C@]12CCC3[C@@H](CC[C@@H]4[C@]3(C)C=CC(N4)=O)[C@@H]1CC[C@@H]2C(NC(C=C(C=C5)C(F)(F)F)=C5C(F)(F)F)=O |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
产品应用
- Dutasteride (marketed as Avodart, Avidart, Avolve, Duagen, Dutas, Dutagen, Duprost) is a 5-alpha-reductase inhibitor that inhibits the conversion of testosterone into dihydrotestosterone (DHT). It is approved for the treatment of benign prostatic hyperplasia (BPH) and is prescibed off-label for the treatment of male pattern baldness (MPB). Avodart is manufactured and marketed by GlaxoSmithKline.
相关文献及参考
- [2]. Biancolella M, et al. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs. 2007 Oct;25(5):491-7.
- [3]. Bramson HN, et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997 Sep;282(3):1496-502.
- [4]. Andriole GL, et al. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol. 2006 May;175(5):1657-62.
- [5]. Margiotta-Casaluci L, et al. Mode of action of human pharmaceuticals in fish: the effects of the 5-alpha-reductase inhibitor, dutasteride, on reproduction as a case study. Aquat Toxicol. 2013 Mar 15;128-129:113-23.
- [1]. Lazier CB, et al. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer
京ICP备2020036287号